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Abstract: Targeted drug delivery requires novel biodegradable, specific binding systems with 
longer circulation time. The aim of this study was to prepare biotinylated poly(lactic acid) (PLA) 
nanoparticles (NPs) which can meet regular requirements as well conjugate more biotins in 
the polymer to  provide better binding with streptavidin. A biotin-graft-PLA was synthesized 
based on previously published biodegradable poly(ethylene glycol) (PEG)-graft-PLA, with 
one polymer molecule containing three PEG molecules. Newly synthesized biotin-graft-PLA 
had three biotins per polymer molecule, higher than the previous biotinylated PLA (#1 biotin 
per polymer molecule). A PEG with a much lower molecular weight (MW ∼1900) than the 
previous biotinylated PLA (PEG MW $ 3800), and thus more biocompatible, was used which 
supplied good nonspecific protein-resistant property compatible to PEG-graft-PLA, suggesting 
its possible longer stay in the bloodstream. Biotin-graft-PLA specifically bound to streptavidin 
and self-assembled into NPs, during which naproxen, a model small molecule (MW 230 Da) 
and hydrophobic drug, was encapsulated (encapsulation efficiency 51.88%). The naproxen-
loaded NPs with particle size and zeta potential of 175 nm and −27.35 mV realized controlled 
release within 170 hours, comparable to previous studies. The biotin-graft-PLA NPs adhered 
approximately two-fold more on streptavidin film and on biotin film via a streptavidin arm both 
in static and dynamic conditions compared with PEG-graft-PLA NPs, the proven nonspecific 
protein-resistant NPs. The specific binding of biotin-graft-PLA NPs with streptavidin and with 
biotin using streptavidin arm, as well as its entrapment and controlled release for naproxen, 
suggest potential applications in targeted drug delivery.
Keywords: targeted drug delivery, bioactive, biodegradable, poly(ethylene glycol) (PEG), 
controlled release, naproxen
Introduction
Biodegradable and specifically bioactive nanoparticles (NPs) are one of the 
  promising routes to realize site-specific drug delivery for cancer or other diseased 
tissues.1–3 To enhance biodegradable NP bioactivity, various chemical modifications 
are   performed on the polymers for NP preparation or directly on NPs,4–6 including 
(1) direct conjugation of targeting biomolecules, eg, antibodies, and (2) attachment of 
ligands or antibodies as arms and further combination with their corresponding central 
elements or receptors, antigens of ligands, or antibodies as targeting   biomolecules. The 
second method is preferred as it maintains bioactivity of the targeting   biomolecules 
to a larger extent.4–6 A widely applied ligand/receptor pair is biotin/streptavidin, 
owing to its high binding affinity (Kd = 10−15 M). Even though streptavidin has been 
incorporated into polymers,7 biotin is more popular due to its simple structure, International Journal of Nanomedicine 2012:7
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Figure  1  The  combination  of  biotin-graft-poly(lactic  acid)  nanoparticles  with 
streptavidin and with biotinylated protein via a streptavidin arm to realize targeted 
drug delivery.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
458
Yan et al
low molecular weight (MW), good reactivity with amine, 
and retained binding property with streptavidin postamina-
tion reaction. In addition, one biotin can easily combine with 
one of four biotin binding sites on tetrameric streptavidin,8,9 
which allows further combination of various commercial-
ized biotinylated proteins acting as targeted molecules.10 
Furthermore, to increase the specific binding between biotin 
and streptavidin and circulation time of NPs in the body, 
some stealth chemicals, eg, poly(ethylene glycol) (PEG)11–13 
and pluronic,14 have been linked to polymers or NPs prior 
to biotin attachment. These can further suppress cellular 
and protein absorption,15 as well as make polymers or NPs 
more water soluble.
Poly(lactic acid) (PLA), one of the few biodegradable 
polymers approved by the Food and Drug Administration, 
has long been applied in NP preparation. However, NPs of 
PLA have no bioactivity. Biotin/(Strept)avidin are the most 
popular molecules used to ascribe it bioactivity. Although 
several studies have reported conjugating biotin with PEG-
block-PLA or pluronic-block-PLA materials, which self-
assemble into NPs and target to steptavidin in vitro,5,6,10,12,13,16–18 
problems still exist: (1) no more than one biotin is attached 
to one PLA molecule, which limits the combination of NPs 
with streptavidin and their targeting function, and (2) the MW 
of PEG used is generally higher than 3800 in order to receive 
good protein resistance and self-assembly function of NPs. 
PEG cannot degraded in the body although it expresses low 
toxicity,19 which limits applications of NPs.20 In addition to the 
lack of bioactivity in PLA NPs, the large amount of residual 
organic solvent and surfactant added during preparation may 
harm cells. It was previously reported that synthesis of PEG-
graft-PLA with low MW of PEG (MW ∼600–1900) and three 
linked PEGs per PLA molecule showed good nonspecific 
protein resistance and self-assembly properties in aqueous 
solution.21,22 PEG-graft-PLA (PEG MW ∼1900) encapsulated 
and realized controlled release of hydrophilic (insulin) and 
hydrophobic (naproxen) chemicals without surfactant and 
minimal use of organic solvent.22
In the current study, the aim was to improve specific 
binding of biotinylated PLA with streptavidin for applica-
tion in targeted drug delivery by conjugating more than 
one biotin to one polymer molecule. It was hoped that the 
received polymer could self-assemble into NPs and entrap 
chemicals which combine specifically with streptavidin and 
biotin via a streptavidin arm (Figure 1). The biotin-graft-PLA 
was synthesized based on PEG-graft-PLA (MW ∼1900) and 
characterized. Self-assembly encapsulation and controlled 
release of naproxen, a small hydrophobic model medicine, 
were studied. Specific binding of biotin-graft-PLA and its 
self-assembled NPs with streptavidin and with biotin via 
a streptavidin arm were evaluated in vitro under static and 
dynamic conditions.
Materials and methods
Polymers and reagents
Biotin, fluorescein 5-isothiocyanate (FITC)-conjugated strepta-
vidin (FITC-streptavidin), N,N′-dicyclohexylcarbodiimide 
(DCC), and N-hydroxysuccinimide (NHS) were obtained 
from Thermo Fisher Scientific Inc (Rockford, IL). 
FITC-conjugated bovine serum albumin (FITC-BSA), 
pyrene, and O,O′-bis-(2-aminopropyl) polypropylene 
glycol-block-polyethylene oxide-block-polypropylene 
glycol (H2 N-PEG-NH2, MW ∼1900) were procured from 
Sigma-Aldrich Co (St Louis, MO). N-methylmorpholine 
was bought from Shanghai Hanhong Chemical Co, Ltd 
(Shanghai, China). PLA, 10% maleic anhydride graft PLA, 
and PEG-graft-PLA were prepared in the lab as described 
previously.21,23 Briefly, PLA was synthesized by melt ring-
open polymerization of D,L-lactide at 140°C for 24 hours 
under vacuum. Maleic anhydride graft PLA was prepared by 
bulk radical reaction initiated by benzoperoxide. PEG-graft-
PLA was obtained by amination of maleic anhydride graft 
PLA with H2 N-PEG-NH2 in tetrahydrofuran at 50°C–55°C 
for 1 hour followed by evaporation of solvent, which was a 
polymeric mixture with low dispersity.
synthesis and characterization  
of biotin-graft-PLA
Biotin (0.14 g), DCC (0.353 g), and NHS (0.197 g)   
dissolved in 5 mL N,N-dimethylformamide (DMF) were International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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allowed to react at room temperature overnight. The   product 
was   centrifuged at 2000 rpm for 5 minutes to remove 
white   precipitate. The supernatant was precipitated with 
diethyl ether followed by four times recrystallization with 
  isopropanol. A white and water soluble crystal of biotin 
NHS ester was received after vacuum drying. Biotin NHS 
(71 mg) was used to react with 0.5 g of PEG-graft-PLA at 
40°C for 72 hours in 1 mL DMF. Excessive biotin NHS 
was removed by   dissolving the   products in distilled water 
twice. The product was vacuum-dried to yield a white and 
nontransparent solid biotin-graft-PLA, which was soluble in 
tetrahydrofuran, DMF, and dimethyl sulfoxide.
Ninhydrin assay was used to confirm the reaction and 
quantify the free amine content in PEG-graft-PLA and biotin-
graft-PLA according to the standard curve of H2 N-PEG-NH2 
as described previously.21 The absorption of yielded purple 
matter was tested at 562 nm (Lambda 900 Spectrometer; 
PerkinElmer Inc, Waltham, MA). Differential scanning 
  calorimetry measurements were carried out on a thermal 
analyzer (Q200 Differential Scanning Calorimeter; TA 
Instruments, New Castle, DE) at a heating rate of 5°C/minute 
from 0°C to 80°C.
To evaluate the hydrophilicity, the advancing water 
  contact angle was tested with sessile drop method 
(100-00-115 Contact Angle Goniometer; Ramé-Hart Instru-
ment Co, Netcong, NJ). The surfactivity and possibility to 
encapsulate chemicals was assessed according to critical 
micelle concentration which was determined using estab-
lished fluorescence method with pyrene as an extrinsic 
probe.24 Serial solutions with fixed pyrene concentration 
of 6.0 × 10−7 M and   various concentrations of biotin-graft-
PLA between 5.0 × 10−6 mg/mL and 5.0 × 10−2 mg/mL were 
prepared. The excitation intensity of pyrene at 338 nm and 
336 nm was obtained (LS 50B Fluorescence Spectrometer; 
PerkinElmer), according to the scanning excitation spectrum 
between 300 nm and 360 nm, by fixing the emission spectrum 
at 395 nm and the excitation and emission bandwidth at 5 nm. 
Critical micelle concentration was determined by taking the 
midpoint in the plot of the intensity ratio of 328/326 to the 
logarithm concentration of biotin-graft-PLA.
Preparation and characterization of 
biotin-graft-PLA and Peg-graft-PLA NPs
Pyrene- and naproxen-loaded NPs in biotin-graft-PLA or 
PEG-graft-PLA, which were respectively used to conduct 
specific binding and drug encapsulation tests, were prepared 
by self-assembly method. In brief, 10 mg of biotin-graft-PLA 
or PEG-graft-PLA and 0.1 mg of pyrene or 0.8 mg of 
naproxen were dissolved in 1 mL acetone and dropped 
into 10 mL distilled water under constant stirring. After 
  evaporation of acetone and centrifugation at 3000 rpm to 
remove unloaded pyrene or naproxen, NPs were obtained. 
Native NPs were prepared with the same procedure but 
without pyrene and naproxen.
The morphology of various NPs was observed by a trans-
mission electron microscope (Tecnai 10; Philips, Amsterdam, 
the Netherlands) at 80 kV after staining with 2% sodium 
phosphotungstate for 3 minutes. Average size and zeta 
potential of NP solution were tested at room temperature by 
a dynamic light scattering instrument (Zetasizer Nano S90; 
Malvern Instruments Ltd, Malvern, UK) using argon ion 
laser. The stability of NPs under dilution (in aqueous solu-
tions with phosphate buffered saline) or pH change (acidic 
and basic conditions) were studied based on the fact that 
the NPs dilute or encounter an acidic or basic environment 
besides the neutral condition when introduced into the body. 
It was delineated as average particle size and zeta potential 
change before and after dilution (10 or 100 times) or pH 
change (4.5 or 10.5, adjusted with 0.1 N hydrochloride or 
sodium hydroxide, respectively).
To test the encapsulation efficiency of naproxen, the 
NPs were centrifuged at 3000 rpm. The sediment which 
contained unencapsulated and insoluble naproxen, but not 
the NPs, was collected and dissolved in DMF. The concen-
tration of naproxen in DMF solution was tested at 331 nm 
(Lambda 900 Spectrometer; PerkinElmer) and used to 
  calculate encapsulation efficiency according to the equation: 
(original naproxen added in NPs preparation – naproxen 
in precipitate – solubility of naproxen in water)/original 
naproxen added in NPs preparation. The cumulative release 
of naproxen was tested with dialysis method at 37°C and 
150 rpm.   Unencapsulated and insoluble naproxen (5 mL) 
was removed from NP solution by centrifuge and placed 
into a dialysis membrane (cutoff MW 8000), and 45 mL 
of 0.01 M phosphate buffered saline was added as dialysis 
solution in a 100-mL conical beaker. Dialysis solution 
(1 mL) was sampled and an equal amount of fresh phosphate 
buffered saline was supplemented at various time points. 
Naproxen concentration was tested at 331 nm where the 
biotin-graft-PLA had no absorbance and was used to calcu-
late cumulative release, which was expressed as percentage 
change of naproxen amount in dialysis solution versus total 
entrapped naproxen over time. Each test was replicated at 
least three times.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Specific binding property of  
biotin-graft-PLA and its NPs
Specific binding of biotin-graft-PLA film  
with streptavidin
Before evaluation of specific binding between biotin-graft-
PLA NPs and streptavidin, the binding of streptavidin on 
biotin-graft-PLA film was tested. The amount of absorbed 
streptavidin and BSA on the surface of polymer films was 
tested. BSA was chosen as a representative nonspecific 
binding protein, due to the fact that albumin is the domination 
protein in human plasma when absorbed on PLA.11 The 
polymer film was formed on glass dish (35 mm) with 6 mg 
of polymer dissolved in 2 mL ethyl acetate after evaporation 
of solvent in air (∼80% humidity) or at 100% humidity for 
96 hours. FITC-streptavidin (3 mL) or FITC-BSA solution 
in dionized water (0.02 mg/mL) was added to glass dish and 
incubated at 37°C for 30 minutes before removal. The film 
was repetitively washed with dionized-water until fluorescent 
intensity was lower than 10, monitored by spectrofluorometer 
(LS-50B; PerkinElmer). The fluorescence on polymer film 
was observed with an inverted fluorescence microscope 
(Olympus IX71; Olympus Corporation, Tokyo, Japan) 
followed by spectrofluorometer (LS-50B; PerkinElmer) at 
510 nm with 490 nm excitation after dissolving in 3 mL of 
tetrahydrofuran. The amount of absorbed FITC-streptavidin 
or FITC-BSA on the polymer film was calculated according 
to their fluorescent standard curves. PEG-graft-PLA was 
used as control material. Each absorption test was replicated 
three times.
Specific binding of biotin-graft-PLA NPs to 
streptavidin and to biotin via streptavidin arm 
under static and dynamic conditions
To understand the specific binding of biotin-graft-PLA 
NPs with streptavidin as well as with biotin via streptavidin 
arm, the amount of biotin-graft-PLA NPs or streptavidin-
incubated biotin-graft-PLA NPs (biotin-graft-PLA NPs-S; 
0.1 mg [1 mL of 1 mg/mL] at room temperature for 
30   minutes) adhered on streptavidin- or biotin-coated glass 
slide was tested under static and dynamic conditions. The 
pyrene encapsulated NPs were used which allowed testing of 
the adhered NPs with the fluorescent method. The streptavidin 
or biotin was coated on glass slide with 0.5 mL of streptavi-
din or biotin solution in DMF (0.2 mg/mL), after evaporation 
of DMF under vacuum. The binding of biotin-graft-PLA NPs 
or biotin-graft-PLA NPs-S on streptavidin- or biotin-coated 
slides was performed at room temperature for 60 minutes 
with 1 mL of original NPs (for static condition) or 10 mL 
of 10× distilled water diluted NPs (for dynamic condition) 
to mimic the in vivo static and dynamic state. A traditional 
parallel flow chamber25 which supplied a shear stress 
of ∼1.0 Pa, middle range value of shear stress in many tissues 
like blood vessels and bone,26 was used to realize dynamic 
incubation. A streptavidin- or biotin-coated glass slide was 
fixed in the bottom of the chamber on which the NP solu-
tion was flowing. Once binding was complete, the slide was 
collected, washed with 5 mL of distilled water three times, 
and dried under vacuum. DMF (5 mL) was used to dissolve 
the adhered NPs and the fluorescent intensity was tested 
with fluorescence spectrophotometry with the excitation/
emission set of 329/392 nm (LS 50B, PerkinElmer). The 
PEG-graft-PLA NPs or streptavidin-incubated PEG-graft-
PLA NPs (PEG-graft-PLA NPs-S; obtained with the same 
method as biotin-graft-PLA NPs-S) were used as control. 
The binding of biotin-graft-PLA NPs on streptavidin or 
biotin-graft-PLA NPs-S on biotin was normalized with 
PEG-graft-PLA NPs or PEG-graft-PLA NPs-S. Each test 
was replicated three times. Statistical significance was 
determined using   Student’s two-tailed t-test. Statistical 
significance was defined as P , 0.05.
Results
synthesis of biotin-graft-PLA
Biotin-graft-PLA was synthesized by reaction of biotin-
NHS ester with amines in PEG-graft-PLA. Ninhydrin 
assay showed that the amine in PEG-graft-PLA reacted 
with biotin. Differential scanning calorimetry showed 
its glass transition appeared at 30.7°C, different from 
the 25.3°C of PEG-graft-PLA (Supplement 1). The con-
tact angle was 66°C, much higher than PEG-graft-PLA 
which was too low to be detected (Supplement 2) due 
to biotin exposure.   Critical micelle concentration was 
7.1 × 10−4 mg/mL (Figure 2), lower than PEG-graft-PLA   
(2.0 × 10−3 mg/mL).
Preparation and characterization of 
biotin-graft-PLA and Peg-graft-PLA NPs
Biotin-graft-PLA and PEG-graft-PLA NPs encapsulated 
with naproxen were spherical in shape as observed by 
transmission electron microscope (Figure 3). Representa-
tive size and zeta potential of pyrene-loaded NPs were 
297.5 nm and −29.13 mV for biotin-graft-PLA NPs and 
278.0 nm and −23.77 mV for PEG-graft-PLA NPs, repre-
sentative size and zeta potential of naproxen-loaded NPs 
were 175 nm and −27.35 mV for biotin-graft-PLA NPs 
and 164.3 nm and −26.64 mV for PEG-graft-PLA NPs, International Journal of Nanomedicine 2012:7
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and representative size and zeta potential of native NPs 
were 161.6 nm and −37.56 mV for biotin-graft-PLA NPs 
and 114.7 nm and −27.84 mV for PEG-graft-PLA. The 
naproxen-loaded biotin-graft-PLA NPs were stable in dilu-
tion for 10× , 100× , and pH range 4.5–10.5 (Figure 4), sug-
gesting its stability under dilution and any pH change 
that may result from tissue fluid when introduced into the   
body.
Encapsulation efficiency of naproxen in biotin-graft-PLA 
NPs was 51.88%, similar to the 50.2% of PEG-graft-PLA. 
Naproxen realized controlled release in 170 hours 
(Figure 5).
Specific binding of biotin-graft-PLA  
and its NPs
The amount of absorbed FITC-streptavidin, and not FITC-
BSA, was about twice that on biotin-graft-PLA film than on 
PEG-graft-PLA film, irrespective of whether the polymer 
was dried at 80% or 100% humidity. In detail, the absorbed 
streptavidin on polymer films was 2.20 × 10−4 g/m2 on biotin-
graft-PLA and 1.11 × 10−4 g/m2 on PEG-graft-PLA when 
polymers were dried at 80% humidity; 2.16 × 10−4 g/m2 
on biotin-graft-PLA and 1.09 × 10−4 g/m2 on PEG-graft-
PLA when polymers were dried at 100% humidity. The 
absorbed BSA on polymer films was 3.50 × 10−4 g/m2 on International Journal of Nanomedicine 2012:7
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biotin-graft-PLA and 3.63 × 10−4 g/m2 on PEG-graft-PLA 
when polymers were dried at 80% humidity; 3.41 × 10−4 g/m2 
on biotin-graft-PLA and 3.59 × 10−4 g/m2 on PEG-graft-PLA 
when polymers were dried at 100% humidity. Due to the 
proven anti-nonspecific protein property of PEG-graft-PLA 
polymer from previous experiments,21 nonspecific protein 
resistance and specific streptavidin binding property of 
biotin-graft-PLA material could be inferred.
Under static and dynamic conditions, biotin-graft-PLA 
NPs bound 1.6- and 1.4-fold more on streptavidin film 
  compared to PEG-graft-PLA NPs; while 2- and 2.5-fold more 
biotin-graft-PLA NPs-S adhered on biotin film than PEG-
graft-PLA NPs-S (Figure 6). The results showed biotin-graft-
PLA NPs and biotin-graft-PLA NPs-S bound specifically to 
streptavidin and biotin respectively, which implied potential 
targeting of biotin-graft-PLA NPs and biotin-graft-PLA 
NPs-S to streptavidin and biotin in vivo.
Discussion
Although several studies have reported self-assembling NPs 
with attached biotin to the end of PLA via PEG or pluronic 
spacer,5,6,10,12,13,16–18 no study has reported more than one biotin 
incorporated into one PLA molecule to enhance its binding 
and potential targeting to streptavidin. In this study, three 
biotins were linked to one PLA with step by step graft reac-
tion. In addition, to increase biocompatibility a lower MW 
PEG was used compared with the previously synthesized 
biotinylated PLA. Biotin-graft-PLA resisted nonspecific 
protein absorption, inferring a longer stay in the circulation 
system compared with PLA. The results also demonstrate 
good surfactivity of biotin-graft-PLA and its feasibility to 
load and control release naproxen with similar effects as that 
of previous studies27–29 and PEG-graft-PLA.21 In particular, 
specific binding of biotin-graft-PLA NPs with streptavidin 
and with biotin via a streptavidin arm was confirmed with 
developed static and dynamic systems.
Biotin was conjugated by activation with DCC and NHS 
first and then crosslinked with amine of PEG-graft-PLA. 
DCC has long been used to couple amines and carboxyl 
groups,30,31 and it exhibits high coupling efficiency with 
hydrolysis of carboxyl groups being the major competing side 
reaction. A two-step crosslinkage reaction was applied here to 
reduce the side reaction of DCC and NHS on PEG-graft-PLA. 
Ninhydrin assay, differential scanning calorimetry, and 
contact angle tests confirmed the reaction (Supplement 1 
and 2). Conjugation of biotin has markedly decreased the 
hydrophilicity of PEG-graft-PLA (Supplement 2). However, 
nonspecific protein-resistant and self-assembly properties 
were maintained due to contained PEGs (Figure 2), which 
enhanced its feasibility to load medicine via hydrophilic/
hydrophobic interaction and possible longer stay of self-
assembled NPs in the circulation system of the body.
During in vitro binding test of streptavidin on biotin-
graft-PLA film and its NPs on a streptavidin-coated slide, 
a much lower molar amount of streptavidin than biotin on 
biotin-graft-PLA was used because it was hoped that biotin-
graft-PLA and its NPs could target to streptavidin as it would 
in vivo, considering that the concentration of streptavidin 
in targeted organ/tissue is generally very low. The results 
suggest that biotin-graft-PLA and its NPs could target to a 
streptavidin-containing position even at low concentrations 
(Figure 6). Similarly, much lower molar amount of streptavidin International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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than biotin in   combination of biotin-graft-PLA NPs-S with 
biotin was applied where it was still found that biotin-graft-
PLA NPs-S bound specifically with biotin, suggesting the 
biotin-graft-PLA NPs-S could target to a biotin-containing 
position. In addition, it was found that biotin-graft-PLA and 
PEG-graft-PLA films dried in high humidity (100%) absorbed 
less streptavidin and BSA compared with films dried in low 
humidity (80%). The reason may be that PEG extended more 
on the surface of film during drying in high humidity which 
expressed better protein resistance. It was also found that 
BSA absorbed about 1.6–3.3-fold more than streptavidin both 
on biotin-graft-PLA and PEG-graft-PLA films, which was 
thought to be induced by differences in protein structure.
PEG-graft-PLA polymer bioactivated with biotin first 
and then formed NPs by self-assembly method (termed as 
two-step bioactivated PLA NPs) in this study, even though 
biotin could be directly linked to the NPs of PEG-graft-PLA 
via the same reaction (termed as one-step bioactivated PLA 
NPs). This was because the aim was to prepare bioactive 
PLA material that could be used in drug delivery as well as 
in tissue engineering. Biotin on the biotin-graft-PLA could 
be inside or outside when self-assembled into NPs. However, 
according to in vitro binding tests of NPs with streptavidin 
(Figure 6), it was inferred that biotin appeared at least partly 
outside of biotin-graft-PLA NPs. But whether the two-step or 
the one-step bioactivated PLA NPs contained more outside 
biotin needs further study. No matter the process, a more 
biotin-conjugated PLA was developed, which provided 
opportunity to have more outside biotin in its NPs and a bet-
ter potential targeting function compared with the previously 
reported biotinylated PLA.
Biotin has been conjugated to the end of PEG-block-PLA 
(PEG MW $ 3800)13 and received bioactivity via the interac-
tion of biotin/avidin pair. Attachment of biotinylated arginine-
glycine-aspartic acid via avidin spacer in biotin-block-PLA 
improved cell adhesion10 and proliferation.18 Self-assembled 
NPs of biotinylated PEG-block-PLA plus PEG-block-PLA for 
paclitaxel entrapment targeted to brain cancer cells in vitro, via 
the combination of biotin and neutravidin,13 achieved entrap-
ment efficiency over 90% and controlled release in 8 hours. 
The biotinylated pluronic-block-PLA self-assembled NPs 
showed potential targeting function by way of biotin-avidin 
interaction.14 The biotin-graft-PLA NPs in this study received 
entrapment and controlled release of naproxen for over 50% 
and 170 hours. Furthermore, the more conjugated biotin in 
biotin-graft-PLA along with its good biocompatibility may 
entrust its   application in targeted drug delivery, even though 
further confirmation is needed. For example, biotin-graft-PLA 
NPs can be used to target to acute and chronic inflammatory 
tissue, where selectins are localized and carefully regulated 
expressed by conjugation with biotinylated sialyl-LewisX, a 
highly specific receptor for selectin via streptavidin arm, so as 
to reduce the gastrointestinal side effects such as ulcer caused 
by anti-inflammatory drugs.32 Similarly NPs can target to brain 
glioma by conjugation with biotinylated transferrin, a mono-
meric glycoprotein with receptor that is overexpressed in brain 
capillary endothelium and at the surface of proliferating cells 
such as brain tumor cells, especially glioblastoma multiforme,16 
via a streptavidin arm. In addition, due to the appearance of bio-
tin on outside biotin-graft-PLA NPs and the encapsulation for 
hydrophobic fluorescent naproxen and pyrene, the application 
of NPs in vivo detection system by way of fluorescent and opti-
cal imaging methods would be expected.17,33 Biotin-graft-PLA 
could also be used as coating on tissue engineering substrate or 
directly used to fabricate substrate to control growth of cells, 
especially for the attachment of biotinylated cells.34
Conclusion
Biotin-graft-PLA, with three biotins in one polymer molecule 
synthesized using a low MW PEG (MW ∼1900), showed 
good nonspecific protein resistance and specific streptavidin 
binding property. It self-assembled into NPs during which 
naproxen was loaded in and realized encapsulation effi-
ciency of  51.88% and controlled release within 170 hours. 
Biotin-graft-PLA NPs bound specifically to streptavidin and 
to biotin using streptavidin arm in both static and dynamic 
conditions in vitro.
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Figure S1 Differential scanning calorimetry curves of biotin-graft-poly(lactic acid) (A) and poly(ethylene glycol)-graft-poly(lactic acid) (B).
AB
Figure S2 The contact angle comparison of biotin-graft-poly(lactic acid) (A) and 
poly(ethylene glycol)-graft-poly(lactic acid) (B).
Supplement figures
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
465
Biotin-graft-PLA nanoparticles bind to streptavidin